An Open-Label, Rater-Blinded, Flexible-Dose, 8-Week Trial of Escitalopram in Patients With Major Depressive Disorder With Atypical Features

Documenti analoghi

• An Open-Label, Rater-Blinded, Augmentation Study of Aripiprazole in Treatment-Resistant Depression
  di: Patkar, Ashwin A., et al.
  Pubblicazione: (2006)
• Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study
  di: Han, Changsu, et al.
  Pubblicazione: (2008)
• History of Depressive and Anxiety Disorders and Paroxetine Response in Patients With Irritable Bowel Syndrome: Post Hoc Analysis From a Placebo-Controlled Study
  di: Marks, David M., et al.
  Pubblicazione: (2008)
• A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
  di: Han, Changsu, et al.
  Pubblicazione: (2018)
• Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
  di: Han, Changsu, et al.
  Pubblicazione: (2020)